Teva Announces Favorable United Kingdom Court Ruling In COPAXONE® Patent Litigation Proceeding

Loading...
Loading...
Teva Pharmaceutical Industries Ltd.
TEVA
announced that the United Kingdom High Court of Justice issued a decision in favor of Teva in a patent litigation proceeding against Generics (UK) Limited, a subsidiary of Mylan Laboratories Inc., on July 11, 2012. Generics (UK) Limited commenced the proceeding in the UK to seek the revocation of European Patent (UK) 762,888, a patent for COPAXONE® (glatiramer acetate injection) expiring May 23, 2015, and to obtain a declaration that its proposed generic version of COPAXONE® would not infringe the ‘888 patent. The High Court specifically determined that the asserted claims of the ‘888 patent were valid, and also declined to issue a declaration that Generics UK's proposed generic version of COPAXONE® would not infringe the ‘888 patent.
Posted In: NewsFDAGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...